In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
Share
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
DLA CIO: Securing AI Pipelines Is Now a Core Mission
With small vendors comprising most of its supplier base, Roberts says stronger oversight and zero-trust controls are critical to counter cyber threats.
6m watch -
How to Thrive in Cybersecurity Without Burning Out
Explore mental health in cybersecurity including imposter syndrome, burnout, boundaries and building a sustainable career in high-pressure tech environments.
34m watch -
Project ARIA Pushes AI From Concept to Soldier-Ready Capability
Army CTO Gabe Chiulli explains how Project ARIA is accelerating AI adoption, cutting red tape and delivering tools to soldiers at speed.
20m watch -
Former Federal Tech Leaders Push for Government Delivery Reform
After leaving government in 2025, April Harding and Maureen Klovers launched We The Doers to elevate frontline expertise and strengthen modernization efforts across agencies.
12m watch
